top of page

The registered randomized study

A 112-patient randomized study, funded by the U.S. Department of Defense and run at Indiana University, compared standard care with standard care plus the electroceutical dressing.

Registry facts

Registry ID: NCT04794621

Sponsor: Indiana University

Collaborators: United States Department of Defense; Naval Medical Research Center

Enrollment: 112 participants (actual)

Dates: Started June 3, 2021; completed July 7, 2023

Design: Randomized, parallel-group; biofilm analysis was performed by outcome assessors blinded to study group (single masking, per the registry).

Comparator: Standard of care alone

Sequential intervention: Standard of care plus PED-10 (Pavaka’s Gen 1 dressing) for three weeks, then a follow-on dressing for three additional weeks

Registry primary outcome: “Response to the use of EDT treatment in prevention of wound biofilm infection” (EDT: electroceutical dressing technology); six-week time frame

U.S. Department of Defense seal

Funded by the U.S. Department of Defense

Reported finding

In a 112-patient randomized study funded by the U.S. Department of Defense (NCT04794621), biofilm was measured during the first three weeks, when patients received Pavaka’s Gen 1 dressing. Biofilm abundance fell 40% from the first visit to week 3 in patients on the Gen 1 dressing plus standard care, while the standard-care group did not improve. Full results are being prepared for peer-reviewed publication.​

Biofilm results come from the first three weeks of the six-week protocol, when patients used the Gen 1 dressing, and cannot be assumed to apply to later designs. Gen 2 has not been studied in patients.

Biofilm abundance at baseline and week 3, standard care vs Pavaka Gen 1 dressing (NCT04794621)
Wound infection burden, standard care vs Pavaka Gen 1 dressing (NCT04794621)

Investigational device. Not cleared or approved by the U.S. FDA; not available for sale. This is not a recruitment or access page.

bottom of page